表紙
市場調査レポート

再発性多発性硬化症(RMS):パイプライン製品の分析

Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 269901
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
再発性多発性硬化症(RMS):パイプライン製品の分析 Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015
出版日: 2015年11月30日 ページ情報: 英文 70 Pages
概要

再発性多発性硬化症(RMS)は、脱髄を引き起こす中枢神経系の炎症に起因します。脱髄は神経インパルスの伝達を遅らせ、多発性硬化症の症状を誘発します。症状には、筋力低下、視覚障害、平衡障害、腸または膀胱制御の喪失が含まれます。

当レポートでは、再発性多発性硬化症(RMS)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

  • 調査範囲

再発性多発性硬化症(RMS)の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

再発性多発性硬化症(RMS):企業で開発中の治療薬

再発性多発性硬化症(RMS):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

再発性多発性硬化症(RMS):企業で開発中の製品

再発性多発性硬化症(RMS)の治療薬開発に従事している企業

  • BIOCAD
  • Cognosci, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Mallinckrodt plc
  • Receptos, Inc.
  • Teva Pharmaceutical Industries Limited

再発性多発性硬化症(RMS):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • COG-133
  • corticotropin
  • DC-TAB
  • glatiramer acetate
  • GZ-402668
  • interferon beta-1a
  • ocrelizumab
  • ozanimod
  • peginterferon beta 1a

再発性多発性硬化症(RMS):パイプラインのアップデート

再発性多発性硬化症(RMS):休止中のプロジェクト

再発性多発性硬化症(RMS):中止された製品

再発性多発性硬化症(RMS):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7370IDB

Summary

Global Markets Direct's, 'Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015', provides an overview of the Relapsing Multiple Sclerosis (RMS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Relapsing Multiple Sclerosis (RMS)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Relapsing Multiple Sclerosis (RMS) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Relapsing Multiple Sclerosis (RMS)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Relapsing Multiple Sclerosis (RMS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Relapsing Multiple Sclerosis (RMS) Overview
  • Therapeutics Development
    • Pipeline Products for Relapsing Multiple Sclerosis (RMS) - Overview
  • Relapsing Multiple Sclerosis (RMS) - Therapeutics under Development by Companies
  • Relapsing Multiple Sclerosis (RMS) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Relapsing Multiple Sclerosis (RMS) - Products under Development by Companies
  • Relapsing Multiple Sclerosis (RMS) - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Actelion Ltd
    • BIOCAD
    • Cognosci, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Genzyme Corporation
    • Merck KGaA
    • Pfenex Inc.
    • Receptos, Inc.
    • VivaCell Biotechnology Espana S.L.
  • Relapsing Multiple Sclerosis (RMS) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles ABT-555 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cladribine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COG-133 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DC-TAB - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GZ-402668 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon beta-1a - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon beta-1b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ocrelizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ozanimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • peginterferon beta 1a - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-726 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ponesimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VCE-0032 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Relapsing Multiple Sclerosis (RMS) - Recent Pipeline Updates
  • Relapsing Multiple Sclerosis (RMS) - Dormant Projects
  • Relapsing Multiple Sclerosis (RMS) - Discontinued Products
  • Relapsing Multiple Sclerosis (RMS) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 08, 2015: Roche's ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis
      • Dec 22, 2014: Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
      • Jun 09, 2014: Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
      • Jan 06, 2014: Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
      • Jun 05, 2013: Receptos Provides Update On Progress Of Lead Product Candidate RPC1063
      • Jan 17, 2012: Genentech Recruits Investigators For Two Phase III Studies Comparing Ocrelizumab To Rebif In People With Relapsing Multiple Sclerosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Relapsing Multiple Sclerosis (RMS), H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by AbbVie Inc., H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Actelion Ltd, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by BIOCAD, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Cognosci, Inc., H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Genzyme Corporation, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Merck KGaA, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Pfenex Inc., H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Receptos, Inc., H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Relapsing Multiple Sclerosis (RMS) Therapeutics - Recent Pipeline Updates, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Dormant Projects, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Relapsing Multiple Sclerosis (RMS), H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top